Search alternatives:
ppm decrease » _ decrease (Expand Search), a decrease (Expand Search), pa decreased (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
5 non » _ non (Expand Search), e non (Expand Search), 3 non (Expand Search)
a non » _ non (Expand Search)
5 nn » 59 nn (Expand Search), 5 nm (Expand Search), 5 n (Expand Search)
ppm decrease » _ decrease (Expand Search), a decrease (Expand Search), pa decreased (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
5 non » _ non (Expand Search), e non (Expand Search), 3 non (Expand Search)
a non » _ non (Expand Search)
5 nn » 59 nn (Expand Search), 5 nm (Expand Search), 5 n (Expand Search)
-
21
-
22
-
23
Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx
Published 2022“…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”
-
24
-
25
-
26
-
27
-
28
Non-Steady-State Fickian Diffusion Models Decrease the Estimated Gel Layer Diffusion Coefficient Uncertainty for Diffusive Gradients in Thin-Films Passive Samplers
Published 2023“…A finite difference model (FDM) developed based on Fick’s second law with non-steady-state (N-SS) flux decreased uncertainty in <i>D</i><sub>Gel</sub> tenfold. …”
-
29
-
30
-
31
-
32
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
33
Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs
Published 2022“…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”
-
34
Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs
Published 2022“…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”
-
35
-
36
-
37
Lower insular perfusion in the DAT group compared with the non-DAT group.
Published 2022“…In the region of interest-based analysis, decrease extent ratios were higher in the DAT group (N = 12) than in the non-DAT group (N = 38) (D). …”
-
38
-
39
-
40